Bharat Biotech submits Covaxin phase 3 trials data to DCGI
Bharat Biotech has submitted data from phase 3 trials of the Covaxin vaccine to the Drugs Controller General of India (DCGI). Covaxin is among three vaccines being used in the nationwide drive against Covid-19.
It was granted approval by the DCGI in January, along with the Oxford University-AstraZeneca Vaccine which is being manufactured by the Pune-based Serum Institute of India (SII) as Covishield.
A third vaccine, Russia’s Sputnik V, was also granted emergency use authorisation (EUA) in April.